Fig. 7: IDO1 inhibition abrogates tumourigenesis in Vil Apc Dock2 mice. | Oncogene

Fig. 7: IDO1 inhibition abrogates tumourigenesis in Vil Apc Dock2 mice.

From: Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression

Fig. 7: IDO1 inhibition abrogates tumourigenesis in Vil Apc Dock2 mice.

A Schematic outlining IDO inhibitor (1-L-MT) treatment regimen in Vil Apc Dock2 mice. B Representative H&E-stained colonic swiss rolls, detailing tumour burden in vehicle and IDO1 inhibitor (1-L-MT) treated Vil Apc Dock2 mice (black arrows). Scale bars are 2.5 mm. C Tumour number in vehicle and IDO1 inhibitor treated Vil Apc Dock2 mice. D Total tumour burden in vehicle and IDO1 inhibitor treated Vil Apc Dock2 mice. N = 8 vs 8 mice. E A model outlining the proposed role of Dock2 in suppressing inflammation induced colorectal cancer. Data represented as mean and error bars SD. All statistical analysis for this figure was performed using two-tailed Mann–Whitney test. Exact p values are indicated in the panels.

Back to article page